Atossa Therapeutics, Inc.

Atossa Therapeutics develops medicines for unmet medical needs in oncology, focusing on breast cancer in women. Lead candidate (Z)-endoxifen is in Phase II trials to treat and prevent breast cancer. The company also works on immunotherapy/chimeric antigen receptor therapy programs. Founded in 2008, Atossa is headquartered in Seattle, Washington.

Overview

Sector

Biotechnology

Target Price

- USD

Current Price

0.8 USD

Potential

Strengths

Price to book ratio (1.18) is lower than the sector mean (24.44).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company has high debt. Net Debt to EBITDA Ratio (2.36) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	-
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	-

Atossa Therapeutics, Inc.

Overview

Strengths

Weaknesses

Key Financial Data